Bo Zhou

Dr. Bo Zhou

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2025 in Cancer Medicine
Verified
Journal Article
Open access
BZBo Zhou
Bo Zhou
ARAmit D. Raval
Amit D. Raval
YZYifan Zhang
Yifan Zhang
MKMatthew J. Korn
Matthew J. Korn
NSNethra Sambamoorthi
Nethra Sambamoorthi
USUsha Sambamoorthi
Usha Sambamoorthi
Objective: This study evaluated treatment patterns and factors associated with androgen deprivation therapy (ADT) intensification with androgen receptor pathway inhibitors (ARPI) and/or docetaxel among older men with mHSPC in the United States. Methods: The study utilized a retrospective cohort of 6850 older men (age ≥ 67 years) diagnosed with mHSPC between July 2016 and December 2019 from the Surveillance, Epidemiology, and End Results Medicare‐linked database. Men must maintain continuous enrollment in Medicare fee‐for‐service Parts A/B/D for ≥ 12 months before mHSPC diagnosis and ≥ 6 months after diagnosis. Initial treatment was classified as ADT alone, ADT + ARPI, or ADT + docetaxel. Factors associated with initial treatment were examined using multivariable multinomial logistic regression. Results: The study cohort (mean age = 76.6 years, SD = 7.0) was mostly non‐Hispanic white (77.7%), followed by non‐Hispanic Black (8.4%) and Hispanic (6.5%). 30.4% received no systemic drug therapy within 6 months of mHSPC diagnosis, 47.1% received ADT alone, 14.8% received ADT + ARPI, and 5.9% received ADT + docetaxel. Among men treated with ADT, there was an increase in ADT + ARPI treatment from 19.0% to 30.0% and a concomitant decline in ADT monotherapy from 72.1% to 62.6% between 2017 and 2019, while ADT + docetaxel treatment marginally decreased from 8.8% to 7.3%. In multinomial logistic regression, men with de novo mHSPC were more likely to receive ADT + docetaxel (aOR = 2.73, 95% CI = [2.07, 3.60]) or ADT + ARPI (aOR = 1.56, 95% CI = [1.32, 1.84]); whereas men with higher frailty index were less likely to receive ADT + docetaxel (aOR = 0.93, 95% CI = [0.91, 0.95]) or ADT + ARPI (aOR = 0.97, 95% CI = [0.96, 0.98]). Specifically, ADT + ARPI was less likely to be utilized among the lower socio‐economic status groups. Conclusions: Three in 10 older men with mHSPC received no systemic treatment. Although there was a gradual uptake of ARPIs, monotherapy with ADT was still highly prevalent, suggesting the integration of intensified treatment is still suboptimal. Targeted interventions are necessary to enhance guideline adherence among older and frail men with mHSPC.

MPMona Pathak
Mona Pathak
Sophie MitraSophie Mitra
Sophie Mitra
JPJahnavi Pinnamraju
Jahnavi Pinnamraju
PFPatricia Findley
Patricia Findley
RWR. Constance Wiener
R. Constance Wiener
Usha SambamoorthiUsha Sambamoorthi
Usha Sambamoorthi
Inflation generates stress, which may lead to high rates of anxiety and depression. Given the recent surge and subsequent decline in the inflation rate in the United States, the prevalence of stress due to inflation may vary, as well as its relationship with anxiety and depression. Therefore, we investigated the prevalence of stress due to inflation and its association with anxiety and depression over time among working-age adults in the United States. We conducted a repeated cross-sectional analysis using Household Pulse Survey (HPS) data for the following weeks: Week 50 (5–17 October 2022) and Week 57 (26 April–8 May 2023). The HPS includes questions about individuals’ stress levels due to price increases in the past two months. We used logistic regressions to examine the association of stress (moderate or high stress versus little or no stress) due to inflation with depression and anxiety among working-age adults controlling for several factors, including demographic factors and social determinants of health. From October 2022 to April–May 2023, the prevalence of stress due to inflation affected more than three quarters of the population (77.7% and 78.7%, respectively). In logistic regressions, we found a significant positive association of stress due to inflation with depression (adjusted odds ratio (AOR) [95% CI] = 2.22 [1.92, 2.57]) and anxiety (AOR [95% CI] = 2.50 [2.18, 2.86]). Despite a decline in the prevalence of both depression and anxiety by three percentage points over the study period, the associations between stress, due to inflation on the one hand, and anxiety and depression, on the other, persisted over time. Stress due to inflation affects more than three-quarters of Americans, and is significantly associated with depression and anxiety. Stress due to inflation is a significant and persistent public health issue.

8 May 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
BZBo Zhou
Bo Zhou
ARAmit D. Raval
Amit D. Raval
YZYifan Zhang
Yifan Zhang
NSNethra Sambamoorthi
Nethra Sambamoorthi
MKMatthew J. Korn
Matthew J. Korn
USUsha Sambamoorthi
Usha Sambamoorthi
Previous research on Radium-223 treatment patterns in metastatic prostate cancer has been limited to select sites, oncology practices, or claims databases. Limited data exists on the use and outcomes of Radium-223 in Medicare population the largest public insurance provider for people aged 65 years and older in the United States. Therefore, this study used a nationwide population database of cancer registries linked to Medicare claims to examine Ra-223 treatment patterns, factors associated with treatment completion, and their associations with survival outcomes. A retrospective cohort analysis was conducted on 1062 Medicare beneficiaries (≥ 66 years) with prostate cancer who initiated Ra-223 treatment between January 2016 and June 2020. Eligible men had 12 months of continuous Medicare Parts A/B/D enrollment prior to Ra-223 initiation and were followed for a minimum of 6 months. Primary outcomes included completion of ≥ 5 cycles of Ra-223 and overall survival. Factors influencing completion were analyzed with multivariate logistic regression, and survival was estimated using Kaplan-Meier and proportional hazards regressions. The cohort was 79.9% nonhispanic White, 6.8% Hispanic, and 6.1% nonhispanic Black, with a mean age of 75.6 years (SD = 6.6). Overall, 59.4% completed ≥ 5 cycles. Men receiving Ra-223 as first-line (21.1%) or second-line metastatic castration-resistant prostate cancer(mCRPC) therapy (44.1%) were more likely to complete treatment than those receiving third-line or later (aOR = 1.76,1.56, 95% CI, [1.22-2.54], [1.17-2.08]). Completing ≥ 5 cycles of Ra-223 was associated with longer survival (18.5 vs. 11.1 months, P < .001; aHR = 0.51, 95% CI, [0.44, 0.59]), as was first- or second-line therapy use (18.4, 14.8 months vs. 13.8 months, P < .001; aHR = 0.56,0.82; 95% CI, [0.45-0.68], [0.69-0.96]) compared to Ra-233 as third-line or later. The majority of men received ≥ 5 cycles of Ra-223. Early initiation of Ra-223 was associated with higher completion rates and better survival outcomes, underscoring the importance of early Ra-223 use in managing mCRPC.

1 January 2026 in Journal of Managed Care & Specialty Pharmacy
Verified
Journal Article
Closed access
NANsima Akpan
Nsima Akpan
BZBo Zhou
Bo Zhou
RRRafia S. Rasu
Rafia S. Rasu
USUsha Sambamoorthi
Usha Sambamoorthi
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) effectively reduce hypoglycemia and offer additional clinical benefits such as weight loss. However, their high costs impose a significant economic burden on both patients and payers. Health care expenditures associated with GLP-1 RA use have not been adequately examined in previous studies. To examine the excess expenditures (total, payer, and out-of-pocket) associated with GLP-1 RA use compared with nonuse among adults with diabetes in the United States. The study design was cross-sectional using data on adults (aged ≥18 years) with diabetes from multiple years (2016, 2018, and 2020) of the Medical Expenditure Panel Survey. Any GLP-1 RA use was derived from prescription medication files. Dependent variables included total, payer, and out-of-pocket health care expenditures. Excess expenditures associated with GLP-1 RAs were estimated using a multivariable generalized linear model (GLM) with gamma distribution and log link. The model adjusted for age, sex, race and ethnicity, social determinants of health, obesity, physical activity, and comorbid conditions. The study sample consisted of 7,670 adults with diabetes, representing approximately 28.6 million individuals in the United States. Overall, 7.5% of adults with diabetes used GLP-1 RAs, with rates increasing from 4.3% in 2016 to 10.6% in 2020. GLP-1 RA users had higher total ($22,029 vs $15,165, P < 0.001), payer ($20,023 vs $13,758, P < 0.001), and out-of-pocket ($2,006 vs $1,407, P < 0.001) expenditures compared with nonusers. Multivariable GLMs indicated that GLP-1 RA users incurred an adjusted excess of $5,417 (P < 0.001), $4,764 (P < 0.001), and $436 (P = 0.001) for total, payer, and out-of-pocket expenditures, respectively. One in 13 adults used GLP-1 RAs. GLP-1 RA users had greater overall, third-party, and out-of-pocket expenditures. These findings underscore the growing economic impact of GLP-1 RA use and highlight the importance of developing strategies that balance the proven clinical advantages of GLP-1 RAs against their financial burden.

11 September 2026 in Healthcare
Verified
Journal Article
Open access
PDF file
MNMichelle Ndiulor
Michelle Ndiulor
HWHao Wang
Hao Wang
RNRolake Neba
Rolake Neba
RRRafia Rasu
Rafia Rasu
BZBo Zhou
Bo Zhou
Usha SambamoorthiUsha Sambamoorthi
Usha Sambamoorthi
Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes mellitus (T2DM). However, its mental health safety profile in routine care, particularly among Medicaid beneficiaries, remains uncertain. We aim to examine the association between glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and newly documented depression diagnosis among adults with type 2 diabetes mellitus (T2DM) enrolled in Medicaid. Methods: We conducted a retrospective longitudinal cohort study using the 2022–2023 Merative™ MarketScan® Multi-State Medicaid Database. Adults aged 18–64 years with T2DM, continuous Medicaid enrollment, and no documented depression during the 2022 baseline period were included. Baseline GLP-1 RA use was assessed in 2022, and newly diagnosed depression was identified in 2023. Associations were estimated using multivariable logistic regression, inverse probability weighting (IPW), and a doubly robust estimator. Results: Among 74,760 eligible adults, 14,953 (20.0%) were GLP-1 RA users. Incident depression occurred in 12.9% of users and 11.1% of non-users (absolute difference, 1.8 percentage points; p < 0.001). GLP-1 RA use was associated with higher odds of newly documented depression diagnosis in multivariable analysis (adjusted OR 1.10, 95% CI 1.04–1.16), IPW analysis (OR 1.09, 95% CI 1.03–1.15), and doubly robust analysis (OR 1.09, 95% CI 1.03–1.15). Conclusions: Baseline GLP-1 RA use was associated with modestly higher odds of a newly documented depression diagnosis during the subsequent year. Prospective studies are needed to determine whether this association is causal.

5 March 2026 in Cancer Epidemiology
Verified
Journal Article
Closed access
BZBo Zhou
Bo Zhou
ARAmitkumar D. Raval
Amitkumar D. Raval
YZYifan Zhang
Yifan Zhang
NSNethra Sambamoorthi
Nethra Sambamoorthi
USUsha Sambamoorthi
Usha Sambamoorthi